An American System for Evidence Generation

Robert M Califf MD Melvin S Cutler Lecture U Mass April 27th, 2017

Personal Perspective


- I have witnessed a revolution in healthcare
- During my professional career
 - Insights into public health measures like blood pressure and fundamentals of diet have advanced dramatically
 - Amazing drugs and devices have been developed and deployed
 - We have taken on the menace of tobacco and we're winning the battle
 - Age specific mortality has been reduced by over 50% with resulting increases in American and global longevity and functional status

The Next Revolution

• Will result from the transformation of information

- In order to apply this fundamental revolution to improve health and quality of life, we must:
 - Learn how to share and create business models that work to improve sharing
 - Invest heavily in curating information
 - Work together to develop social and ethical constructs to deal with privacy, confidentiality and security
 - Create a workforce that can both create new methods and integrate information into practice
 - Give the workforce time to invest in knowledge generation as a routine part of practice
 - Work with the public to gain support and understanding

Mortality in the 20th Century



Eight Americas: Investigating Mortality Disparities across Races, Counties, and Race-Counties in the United States

Christopher J. L. Murray^{1,2,3}, Sandeep C. Kulkarni^{2,4}, Catherine Michaud^{2,3}, Niels Tomijima³, Maria T. Bulzacchelli³, Terrell J. landiorio³, Majid Ezzati^{1,2*}

1 Harvard School of Public Health, Boston, Massachusetts, United States of America, 2 Harvard University Initiative for Global Health, Cambridge, Massachusetts, United States of America, 3 Center for Population and Development Studies, Harvard University, Cambridge, Massachusetts, United States of America, 4 University of California San Francisco, San Francisco, California, United States of America

Funding: This research was supported by a cooperative agreement, awarded by the Centers for Disease Control and Prevention and the Association of Schools of Public Health (grant U36/ CCU300430–23) and by the National Institute on Aging (grant PO1-AG17625). The funders had no role in study design, data collection and analysis, decision to publish, or

ABSTRACT

Background


The gap between the highest and lowest life expectancies for race-county combinations in the United States is over 35 y. We divided the race-county combinations of the US population into eight distinct groups, referred to as the "eight Americas," to explore the causes of the disparities that can inform specific public health intervention policies and programs.

Murray et al. PLoS Med 2006; 3:1513-1524

Mortality Experiences of the 8 Americas


Males

Females




Murray et al. PLoS Med 2006; 3:1513-1524

All-cause mortality, ages 45–54 for US White non-Hispanics (USW), US Hispanics (USH), and six comparison countries: France (FRA), Germany (GER), the United Kingdom (UK), Canada (CAN), Australia (AUS), and Sweden (SWE).




Anne Case, and Angus Deaton PNAS 2015;112:15078-15083





Cost of a Long Life




Economist.com

Print Edition

The Economist - North America Edition






Truth and Expertise

- We are seeing an erosion in public confidence in:
 - Veracity of traditional sources of information
 - The value of credentialed expertise
 - Science itself
- The deluge of information is a key factor

Burning Platform: Overwhelming Complexity



Stead WW. Beyond expert-based practice. IOM (Institute of Medicine). Evidence-based medicine and the changing nature of health care: 2007 IOM annual meeting summary,(Introduction and Overview, p. 19). Washington, DC: The National Academies Press 2008.

Precision Medicine Initiative: Modernizing FDA Regulation of Genomic Laboratory Tests


Traditional testing




Next generation sequencing



Relative Complexity of Therapies







One subunit of a protein

Protein composed of about 1100 subunits

Cell composed of about 3.6 x 10⁶ proteins

10² Atoms

10⁵ Atoms

10¹⁴ Atoms

L-tryptophan Small Molecule Drug IgG antibody molecule Protein Biologic Mesenchymal stem cell Cellular Biologic

CRISPR/Cas9 Gene Editing



- Cas9 nuclease can be directed to cut at specific locations designated by guide RNAs
- Though there is some concern for off-target effects, CRISPR/Cas9 is a powerful technique for altering genes


Short Introduction to Genome Editing

Three major forms of genome editing:

- Zinc Finger Nucleases (mid-2000s)
- TALENs (Transcription activator-like effector nucleases) (late 2000s)
- CRISPR (clustered regulatory interspersed short palindromic repeats and associated enzymatic activities (e.g., Cas9) (2011-2012 depending on whom you ask)


Until these three forms of editing, alteration of genomic DNA could control the *nature* of the change (i.e., sequence-specific alterations), but except for the technically very difficult homologous recombination, neither:

- the specific location (i.e., site-specific alterations), nor
- the exact nature of the change
 - Deletion of specific nucleotides
 - Substitution of nucleotide/s
 - Addition of sequences by insertion at a specific site



Nature Reviews | Microbiology

Drug Discovery and Development Timeline



American Association of Cancer Research 2011 Cancer Progress Report

The Opportunity

- Information technology and "data science" have reached a phase of rapid acceleration
- We can sense, measure, compute, analyze and transmit in a manner that was imaginable only to a few a decade ago
- The translation of this capacity across the translational spectrum is "wide open"
- Technology advances rapidly, people change slowly
- I've never seen a better time to be in translational medicine
- "Luck is what happens when preparation meets opportunity."

The Engine

- Data—abundant and overwhelming
- Information—a lot going into the computer, not much coming out
- Knowledge--< 15% of major clinical decisions informed by high quality information
- Wisdom—how often are we "the emperor with no clothes" given the paucity of evidence
- The time is right to shift the action to the right on this continuum



Precision medicine for the population, and the patient


It is more important to know what sort of person has a disease than to know what sort of disease a person has.

Hippocrates

A Critical Conceptual Issue in Precision Medicine

- Personalized medicine was sold in many quarters as an approach in which deep study of a few people could be generalized to entire populations
- Deep dives into individuals and small groups will remain important, but...
- Precision medicine is evolving with the realization that due to the multidimensional heterogeneity of the problem, in order to devise effective therapies we need deep study of the entire population to find predictive (probabalistic) relationships that can be applied to individuals based on what they have in common with others ("patients like us")

Many tools to dissect individualized health Lowest Food Low Med Med High deserts Highest //// 65-24 Corrido County Lines **Poverty Health records** Tennessee FOODDESSET 485--351 487-899 -45.25 - 21.18 -3.50 - 43.82 200 - 16.05 -0.61 - 1.67 10.10 - 33.4 -11 10- 4.87 128.48 AGCAACAO C G G C A G C A A C A C G A T **Proteomics** CAGCAACACGATCG GCAACACGATCGGCG TCGGCGCCC Aroma GCGCCC CGCC GCGCC CGCCC GCGGCA CAACACGATC GCGCCCGC G C G G C A G C A A C A C G A T C G G C G C C C G C C 1 G C G G C A G C A A C A C G A T C letabolomics Genomics 82 2011-12-25 12:25:01 mHealth nages



The challenge: integrating multiple datasets for discovery and implementation

Big Challenges in Biomedicine

- Lack of significant information over the time dimension Measurements made to assess biology and human health are made periodically in visits to healthcare or research
- Missing systems biology When developing concepts of human biology or drug development we make limited measurements focused on specific mechanisms—we're looking "under the lamppost"
- Missing the ability to measure the interactions of biology, sociology, environment and decision-making that could enable optimization of individualized and population health — Although we know that health and disease are the product of the interactions of genes, multiple derivative biological systems, environment, social context and personal decisions, we tend to look at one part of the time







THE PRECISION MEDICINE INITIATIVE® COHORT PROGRAM

- One million or more volunteers, reflecting the broad diversity of the U.S.
- Opportunities for volunteers to provide data on an ongoing basis
- Data shared freely and fast to inform a broad variety of research studies





Patient Partnerships



EHRs





Technologies


Genomics



Data Science

The Economist

Planet of the Phones



The Economist. Feb 2015

MAPPING HEALTH

The 'Triple Aim'

By Marie Lym Miranda, Jeffrey Ferranti, Benjamin Strauss, Brian Neeton, and Robert M. Califf Geographic Health Information

Systems: A Platform To Support

 DOI:
 10.1377 /Nithe # 2012.1199

 HEALTH AFFAIRS 32,
 N0.9 (2013):1608-1615

 02013 Project HOPE-- The Proplet to Prople Health

 The Proplet on Prople Health
 Foundation, Inc.

Marie Lynn Miranda

(minirand@umich.edu) is dean of and a professor in the School of Natural Resources and Environment and is a professor in the Department of Pediatrics, University of Michigan, in Ann Arbor.

Jeffrey Ferranti is the chief medical information officer and vice president for dinical informatics, and an assistant professor in newborn critical care, at Duke University Medical Center, in Durham, North Cambina.

Benjamin Strauss is an associate in research at the Nicholas School of the Environment, Duke University.

Brian Neelon is a statistician at the Nicholas School of the Environment, Duke University.

Robert M. Califf is vice

chancellor for dinical and translational research and a professor of medicine in the Division of Cardiology, Duke University Medical Center. ABSTRACT Despite the rapid growth of electronic health data, most data systems do not connect individual patient records to data sets from outside the health care delivery system. These isolated data systems cannot support efforts to recognize or address how the physical and environmental context of each patient influences health choices and health outcomes. In this article we describe how a geographic health information system in Durham, North Carolina, links health system and social and environmental data via shared geography to provide a multidimensional understanding of individual and community health status and vulnerabilities. Geographic health information systems can be useful in supporting the Institute for Healthcare Improvement's Triple Aim Initiative to improve the experience of care, improve the health of populations, and reduce per capita costs of health care. A geographic health information system can also provide a comprehensive information base for community health assessment and intervention for accountable care that includes the entire population of a geographic area.


onald Berwick and colleagues' hoodlead exposure; a health services application influential 2008 Health Affairs article, "The Triple Aim: Care, Health, and Cost," describes a conceptual framework developed by the Institute for Heakthcare Improvement for and county levels.

improving the US health care system.¹ In the Triple Aim, the institute has identified three aims that must be simultaneously pursued in prove the experience of care, improve the health of populations, and reduce per capita costs of health care. In this article we introduce and describe information technology designed to support health system sand communities in achieving the Triple Aim. We demonstrate health of technology can be used to assess the health of


MAPPING HEALTH

EXHIBIT 1


Example Of Geographic Health Information Systems (GHIS) For Mapping The Terrain Of Diabetes In Durham County, North Carolina




SOURCE Duke Health Technology Solutions Decision Support Repository (DSR), using information on boundaries and streets layers from the US Census Bureau Geography Division, census 2010; and taxparcel data from the Durham County Jax Assessor_NOTE. The elements of this GHIS map are ex-



Generating Evidence to Inform Decisions




Learning health care systems




www.fda.gov

Historical model of clinical research: Many recruitment sites and a coordinating center

- Hub & spoke model
- Top-down decision-making
- Sites operated independently



Modified Model Data Shared, Sites owned by Health Systems



www.fda.gov

Academic medical centers in the US have become academic health and science systems (AHASs!)—they are no longer ivory towers they are major economic engines and social forces in our society

The "Biomedical Academic System"






Figure 2: Academic health sciences system (AHSS) as a vertically integrated care-delivery system


Dzau et al., "The Role of Academic Health Science Systems in the Transformation of Medicine," The Lancet 375 (March 13, 2010): 951.

Previously Independent Sites now part of large integrated health systems increasingly sophisticated data warehouses




Nodes are Operational Clusters Using Common Data






God at His computer

Drug Surveillance and Trials



Sentinel Distributed Analysis




Sentinel Distributed Database*

- Populations with well-defined person-time for which most medically-attended events are known
- 193 million members**
- 351 million person-years of observation time
- 39 million people currently accruing new data
- 4.8 billion dispensings
- 5.5 billion unique encounters
 - 51 million acute inpatient stays
- 33 million people with <a>>1 laboratory test result

^{*} As of August 2015, excludes HCA and BCBS of Massachusetts


^{**} Double counting exists for individuals who change health plans

Device Surveillance and Trials






National System Paradigm Shift



www.fda.gov



Demonstration Project Overview-NIH Healthcare Systems Research Collaboratory

10 Demonstration Projects spanning 12 NIH institutes and centers

Major clinical outcome trials

1-year planning phase (UH2)


Implementation phase (UH3)

Using EHRs and minimal additional data collection

Log order reduction in cost



PCORnet embodies a "community of research" by uniting people, clinicians & systems




20 Patient-Powered Research Networks (**PPRNs**) 13 Clinical Data Research Networks (**CDRNS**)

PCORnet

A national infrastructure for people-centered clinical research

Resulting in a national evidence system with research readiness



Policy efforts underpinning RWE push

Cures provisions (Sec. 3022)

- Requires FDA to establish a program to evaluate the potential use of real world evidence to:
 - Help support the approval of new indications for an approved drug
 - Help support or satisfy post approval study requirements

PDUFA RWE provisions


- Tracks with Cures Act
- Requires FDA to establish a program to evaluate the potential use of real world evidence to:
 - Help support the approval of new indications for an approved drug
 - Help support or satisfy post approval study requirements

Reinforcing of a Learning Health Care System:

- Doesn't change approval standards, rather it better supports and enables use of data and evidence on outcomes that are hard to get from traditional RCTs (e.g., outcomes that are too costly, too small populations with particular clinical features, too long follow-up needed, diff impact in diff clinical settings, etc.)
- Learning from real-world patient experiences can support better informed health care decision-making by a range of stakeholders

Real World Data vs Evidence

FDA



National Academies of Sciences, Engineering, and Medicine. 2017. *Realworld evidence generation and evaluation of therapeutics: Proceedings of a workshop*. Washington, DC: The National Academies Press. doi: 10.17226/24685

Real World Data and Efficacy



SOUNDING BOARD

Real-World Evidence — What Is It and What Can It Tell Us?

- Real-world evidence can be used across a wide spectrum of research, ranging from observational studies to studies that incorporate planned interventions, whether with or without randomization at the point of care.
- Incorrect to contrast the term "real-world evidence" with the use of randomization in a manner that implies that they are disparate or even incompatible concepts.
- Must consider the components of such trials that are critical to obtaining valid results and minimizing bias.


Laying the Foundation



Data Standards

Stakeholder

Engagement







Guidances Use of Electronic Health

Oraf Record Data in Clinical Investigations

DemonstratioElectronic Source Data in
Clinical Investigations

Use of Electronic Informed Consent

- Organize operational systems that bring together research networks embedded in practice
 - to enable patients, consumers, clinicians, industry, government, and health care systems to participate in prospective trials and observational studies
 - Develop operational/regulatory approaches to facilitate practicebased systems for therapeutic research, safety surveillance, public health, and quality improvement.
 - Support adequate time commitment for clinicians to engage with patients to ensure mutual understanding and appropriate consent
 - Efficient systems for contracting and liability
 - Clinical care and research closely aligned in "learning health system" supported by education and training
 - How can delivery systems with their evolving power create a system that encourages participation in an efficient system?


- Establish a robust framework for privacy, confidentiality, and security
 - endorsed by patients and consumers to ensure the trust a learning health system will require,
 - Robust procedures that ensure data security and protect confidentiality
 - Efficient and thorough digital system of education and research permissions for patients
 - Balance of individual autonomy and public health needs
 - Great start: Precision Medicine Initiative: Privacy and Trust Principles
 - How can delivery systems take on a more constructive role to move the system to a participatory learning system?

- Adopt a common approach to configuring, storing, and reusing digital health care data to enable use in care, research, safety surveillance, and public health
 - As called for in the Nationwide Interoperability Roadmap published by the Office of the National Coordinator for Health Information Technology.
 - Common standards and terminology for prospective data collection
 - Continuous effort to curate data to produce high quality data sets for analysis using common data models
 - Leverage existing digital health/healthcare data to create efficiencies (registries, claims data, EHR data, personal devices)
 - Can delivery systems figure out how to share data at the scale needed now that we understand the needed sample sizes?

- Develop and test new methods to reliably answer research questions
 - more efficient RCTs,
 - Novel designs such as cluster-randomized trials, basket trials
 - And more reliable observational studies aimed at assessment of interventions
 - "Meta-knowledge" on which methods are best for which types of questions
 - By leveraging data already collected by health information technology and other electronic sources to answer research questions or facilitate the conduct of new trials.
 - Will delivery systems value clinical science enough to create the needed work force and reward scholarly activity in this arena?

- Ensure the development of novel approaches focusing on streamlining and harmonizing processes in ways that eliminate barriers that promote unnecessary complexity, while ensuring safeguards that are truly needed.
 - Streamlined and harmonized processes eliminate barriers to efficient research while ensuring needed safeguards
 - Systems for high quality and efficient ethics review and contracting
 - Development of approaches to assuring quality systems through better use of analytics
 - Can delivery systems regard efficiency in research with the same seriousness as they have addressed efficiency in clinical care?

Background



Many of today's patient groups serve as active partners in the clinical trial enterprise and invest private funding in milestone driven research with focus on leveraging their assets to de-risk research and increase return on investment.

PG Engagement Across the Research & Development Continuum

• From Bench to Bedside and Back

- Input re interest of research question to patient community
- Providing data on unmet need & therapeutic burden
- Fundraising and direct funding for research to identify target molecules
- Facilitating collaboration with NIH
- Characterizing the disease & relevant mechanisms of action

- Fundraising & direct funding for research, trial operations support
- Assistance in selecting & recruiting optimum clinical sites
- Clinical infrastructure support
- Helping educate/motivate patient community & recruit for trials
- Providing patient feedback on participant experience
- Serving on Data & Safety Monitoring Board
- Input for any trial adaptations or modifications
- Accompanying sponsor to milestone meetings, e.g., after phase 2 &3

- Serving on post-market surveillance initiatives
- Helping return study results to participants
- Co-presenting results
- Publications/communications re results
- Feedback on how patient community views results
- Natural history database & registry support
- Working with payers re reimbursement

PAS/Outcomes

Pre-Discovery

Pre-Clinical > Ph

Phase 1/2/3

FDA review &


- Fundraising and direct funding for research
- Providing translational tools (assays, cell & animal models, bio-samples, biomarkers, etc.)
- Helping define study's eligibility criteria
- Natural history database & patient registry support
- Input on meaningful clinical endpoints
- Assistance re informed consent form
- Working with FDA re benefit-risk and draft guidance
- Accompanying sponsor to Pre-IND FDA mtg to advocate for study


- Providing public testimony at the FDA Advisory Committee & other FDA hearings
- Preparing submission for newborn screening when appropriate

*Adapted from Parkinson's Disease Foundation materials for CTTI's Patient Groups & Clinical Trials Project

blic testimony dvisory

Data Activation and Testing Outcomes





Verily

Digital Transformation



- Data on premise, hard to access, analyze and use
- Productivity tools built for individual, local usage
- IT focusing on where it computes

- 2020 Collective Intelligence Distributed Computing
- Data stored in cloud, simple to query
- Collaborative, cloud based productivity applications
- Machine learning drives deep, actionable insights
- IT changing **how** it computes


The New Einsteins Will Be Scientists Who Share

From cancer to cosmology, researchers could race ahead by working together—online and in the open

By MICHAEL NIELSEN

In January 2009, a mathematician at Cambridge University named Tim Gowers decided to use his blog to run an unusual social experiment. He picked out a difficult mathematical problem and tried to solve it completely in the open, using his blog to post ideas and partial progress. He issued an open invitation for others to contribute their own ideas, hoping that many minds would be more powerful than one. He dubbed the experiment the Polymath Project.

Several hours after Mr. Gowers opened up his blog for discussion, a Canadian-Hungarian mathematician posted a comment. Fifteen minutes later, an Arizona high-school math teacher chimed in. Three minutes after that, the UCLA mathematician Terence Tao commented. The discussion ignited, and in just six weeks, the mathematical problem had been solved.



Whole Genome Sequencing Program (WGS)



Home > Food > Science & Research (Food) > Whole Genome Sequencing Program (WGS)

On this page:

Introduction

Purposes

Technology

Introduction

Contamination

Science & Research (Food)

Whole Genome Sequencing Program (WGS)

Whole Genome Sequencing Program (WGS)

Projects

Researchers

Events

Whole Genome Sequencing (WGS) Fast Facts



Whole genome sequencing reveals the complete DNA make-up

· Proactive Applications of Whole Genome Sequencing

· GenomeTrakr: Using Genomics to Identify Food

of an organism, enabling us to better understand variations both within and between species. This in turn allows us to differentiate between organisms with a precision that other technologies do not allow. FDA is using this technology to perform basic foodborne pathogen identification during foodborne illness outbreaks and applying it in novel ways that have the potential to help reduce foodborne illnesses and deaths over the long term both in the U.S and abroad.

The most basic application of this technology to food safety is using it to identify pathogens isolated from food or environmental samples. These can then be compared to clinical isolates from patients. If the pathogens found in the food or food production environment match the pathogens from the sick patients, a reliable link between the two can be made, which helps define the scope of a foodborne illness outbreak. This type of testing has traditionally been done using methods such as PFGE, but there are some strains of Salmonella spp. that PFGE is unable to differentiate. Whole genome sequencing performs the same function as PFGE but has the power to differentiate virtually all strains of foodborne pathogens, no matter what the species. Its ability to differentiate between even closely related organisms allows outbreaks to be detected with fewer clinical cases and provides the opportunity to stop outbreaks sooner and avoid additional illnesses

GenomeTrakr

- State and Federal laboratory network collecting and sharing genomic data from foodborne pathogens
- Distributed sequencing based network
- Partner with NIH R NCBI
- **Open-access** genomic reference database
 - http://www.ncbi.nlm.nih.gov/bioproject/183844
- Can be used to find the contamination sources of current and future outbreaks

http://www.fda.gov/Food/FoodScienceResearch/WholeGenomeSequencingProgramWGS/default.htm#trakr

SECTIONS

Q SEARCH HOME

Twitter's C.E.O., Dick Costolo, Is Set to Exit, Feeling Heat of Criticism



ROBOTICA EPISODE 5 Sex Dolls That Talk Back



STATE OF THE ART For Twitter, Future Means Here and Now





Sidewalk Labs, a Start-Up Bold Aims to Improve City

SUBSCRIBE NOW



LOG IN



The New York Times

TECHNOLOGY

For Big-Data Scientists, 'Janitor Work' Is Key Hurdle to Insights

By STEVE LOHR AUG. 17, 2014

PATIENT LEAVES HOSPITAL ALIVE

by Dr James Leftonatrolley

THERE was wide-spread shock today at the news that a patient had left a hospital today without having been killed by a medical error. A spokesman for the hospital said, "This is a very rare occurrence and there is no cause for alarm. We will be launching a full enquiry at once into what went right. We can only apologise to the undertakers." We Want you to be Creative Using Big Data and to be Responsible to Create High Quality Evidence to Support Intervention

